Clinical Trials
Participation in clinical research advances our knowledge of effective treatments and helps us understand the life cycle of diseases.
Inspire Santa Fe Medical is committed to offering our patients the latest treatments through our clinical research division. Every clinical study is monitored and closely follows all FDA clinical practice guidelines for investigating the efficacy of new medications not yet on the market, as well as new uses for existing medications on the market.
Inclusion and involvement in any clinical study are voluntary and may be discontinued at any time by either the participant or study sponsor. Study participants are provided full disclosure of the study parameters, purpose, duration, and side effects If you are interested in learning more about a current trial or upcoming research participation opportunities, please contact us. Our experienced research team will be happy to discuss and answer questions you or your family may have about study objectives.
We are actively recruiting for the following clinical trials:
LG Chem LG-GDCL010: A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
Novartis CAIN457C22301: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
Novartis CAIN457O12301: A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy
Atom Bioscience ABP-671-301: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arth A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout
RA-PROPR: A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR)
If you are interested in participation, please contact our Clinical Research Coordinator for further information:
(505)-908-3807
alundquist@sfrheumatology.com
We are participating in the following trials, but recruitment has ended:
Lilly-I4V-MC-JAJA: A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Horizon HZNP-KRY-202: A Phase 2, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA® (Pegloticase) (MIRROR)
Horizon HZNP-KRY-403: A Phase 4, Multicenter, Open-Label, Infusion Duration Study to Assess Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrollable Gout Receiving Methotrexate.
Acelyrin 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis
